Ryan Cady is the Owner and CEO of Clinvest, a company specializing in research focused on treating pain and inflammation specifically from migraines and TMJ disorders. Prior to their current role, Cady served as a Sr. Research Scientist at Missouri State University from June 2007 to August 2013, where they were the research lead for molecular mechanisms on the role of CGRP and inflammatory peptides in migraine. Ryan also managed clinical trial assay development, execution, and reporting for salivary biomarkers to sponsor.
Before their work at Missouri State University, Cady interned at Allergan Pharmaceuticals from June 2006 to August 2006 in the Drug Safety Evaluation Department, where they looked at potential side effects of new therapeutic drugs.
Cady’s experience in both the private and public sector has given him a well-rounded perspective on research and development within the pharmaceutical industry. Their focus on finding new ways to treat pain and inflammation has made him a respected leader in their field.
Ryan Cady's educational career consists of a Master's in Biology from Missouri State University and a Ph.D in Neurobiology from the University of Wisconsin-Madison.
Some individuals on their team include Addie Wikowsky - Junior Data Manager & Biostatistician, David True - Medical Director, and Amber Bailey - Research Coordinator.
Current role